In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the ...

Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of ...

Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental vaccine for a serious type of skin cancer, when used ...

Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for ...

Halozyme HALO0.47%increase; green up pointing triangle was granted a preliminary injunction that would prevent Merck MRK-0.41%decrease; red down pointing triangle & Co. from distributing a formulation ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...

Keytruda and Padcev combination shows improved event-free and overall survival in muscle invasive bladder cancer patients ineligible for cisplatin. The KEYNOTE-905/EV-303 trial demonstrated ...

Keytruda Qlex (pembrolizumab and berahydaluronidas alfa-pmph) is a prescription drug approved to treat different types of cancer, such as non-small cell lung cancer and head and neck cancer. Keytruda ...

Merck’s MRK strong position in the oncology market is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor contributes over half of the company’s pharmaceutical ...

(Reuters) -Merck and Japan's Eisai said on Wednesday they will shut down a late-stage study testing an experimental combination therapy to treat a type of liver cancer, after interim results showed ...